Lunit, a South Korean leader in AI for cancer diagnostics, has announced a collaboration with Daiichi Sankyo, a Japanese pharmaceutical company, aiming to enhance biomarker discovery and optimize translational research. This partnership, revealed on December 15, 2025, will incorporate Lunit’s advanced digital pathology products, Lunit SCOPE IO® and SCOPE universal IHC® (uIHC), into two of Daiichi Sankyo’s oncology pipeline programs, marking a significant step forward in precision oncology.
The collaboration will leverage various Lunit SCOPE solutions, allowing Daiichi Sankyo to utilize SCOPE uIHC for quantitative immunohistochemistry (IHC) analysis and SCOPE IO for immune phenotyping and spatial analysis. By integrating these AI-powered tools, the companies aim to explore novel biomarkers that could enhance clinical trial processes and support precision patient stratification within their oncology programs.
“Lunit SCOPE was built to unlock hidden insights from pathology slides—quantifying the tumor microenvironment, predicting molecular profiles, and generating data-rich features to inform trial design,” said Brandon Suh, CEO of Lunit. He added that the collaboration is set to facilitate faster biomarker discovery, leading to more efficient clinical trials and improved outcomes for patients by ensuring they receive the most suitable therapies.
The collaborative efforts will include exploratory research projects across multiple types of cancer, potentially informing trial designs, biomarker strategies, and clinical development plans. This partnership underscores the growing trend of integrating AI technologies into the oncology research landscape, promising to transform how cancer treatments are developed and optimized.
Founded in 2013, Lunit has established itself as a global player in cancer diagnostics, offering a suite of clinically validated solutions encompassing medical imaging, breast health, and biomarker analysis. The company aims to empower earlier detection and smarter treatment decisions across the cancer care continuum. Its offerings include the FDA-cleared Lunit INSIGHT suite and various tools that support cancer screening in thousands of medical institutions worldwide.
With its extensive use of AI technology, Lunit’s SCOPE platform has become instrumental in research partnerships with leading pharmaceutical and laboratory organizations, paving the way for significant advancements in biomarker research and companion diagnostic development. Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with evolving data sets, driving measurable impacts for patients, clinicians, and researchers.
This collaboration with Daiichi Sankyo highlights the potential for AI-driven solutions to streamline drug development processes and enhance treatment personalization, which are critical in the ongoing battle against cancer. As the landscape of oncology research evolves, partnerships like this may play a crucial role in accelerating innovation and improving patient outcomes globally.
To learn more about Lunit and its offerings, visit lunit.io/en. Further details on Daiichi Sankyo can be found at daiichisankyo.com.
See also
2025 AI Rollouts: Companies Thrive by Tackling Real Problems, Not Technology Hype
Amazon Launches AI Assistant in Kindle App to Answer Character and Plot Questions
Merriam-Webster Declares “Slop” Word of the Year 2025 Amid AI Content Surge
Marvell Gains Momentum with $3.25B Celestial AI Deal Amid Data Center Growth Concerns
SciBERT Achieves 338,726 Monthly Downloads, Surpassing BioBERT with 90.01 F1 Score
